[Hyp3]-bradykinin and [Hyp3]-Lys-bradykinin interact with B2-bradykinin receptors and stimulate inositol phosphate production in cultured human fibroblasts  by Dengler, Robert et al.
Volume 262, number 1, 11 l-l 14 FEBS 08221 March 1990 
[Hyp3]-bradykinin and [Hyp3]-Lys-bradykinin interact with 
B2-bradykinin receptors and stimulate inositol phosphate production in 
cultured human fibroblasts 
Robert Dengler *, Alexander FauDner, Werner Miiller-Esterl* and Adelbert A. Roscher 
Kina’erklinik im Dr. von Hauner’schen Kinderspital aizr Universitiit Miinchen, Abteiung fur Klinische Biochemie, Lindwurmstraje 4, 
D-8000 Miinchen 2, FRG and *Abteilung fur Klinische Chemie und Klinische Biochemie in a’er Chirurgischen Klinik Innenstadt der 
Universitiit Miinchen, NuJbaumstraBe 20, D-8000 Miinchen 2, FRG 
Received 29 December 1989 
The recently isolated, naturally occurring peptide hormones [Hyp3]-bradykinin and [Hy@]-Lys-bradykinin were investigated for their agonist activi- 
ty on solubilixed binding sites from human fibroblasts. Both ligands competed with PHlbradykinin binding in a dose-dependent fashion with poten- 
cies similar to bradykinin (BK) and Lys-BK. Biological activity was assessed by determination of inositol phosphate accumulation and cyclic 
3’,5’-adenosine monophosphate synthesis in intact cultured cells. Stimulation by the hydroxylated peptides resulted in a pronounced accumulation 
of both parameters with similar effectiveness as BK and Lys-BK. These results indicate that [Hyd]-BK and [Hyd]-Lys-BK are agonists at the 
bradykinin receptor system with properties comparable to their non-hydroxylated analogues. This suggests that hydroxylation of kinins does not 
alter receptor interaction or signal transduction in cultured human fibroblasts. 
Bradykinin; Kinin hydroxylation; B,-receptor; Cyclic adenosine monophosphate; Inositol phosphate 
1. INTRODUCTION 
Kinins are involved in a variety of biological pro- 
cesses such as the regulation of blood pressure, pain, 
neurotransmission, inflammation and cell prolifera- 
tion. They are generated from their precursors, the 
kininogens, by limited proteolysis through the action of 
kallikrein and other trypsin-like serine proteases [l]. 
These effects are mediated through the interaction of 
the ligand with at least two types of receptors, Bl and 
B2 [2]. 
ty to bind to bovine uterine myometrium and in its 
potency on the isolated rat uterus. However, data from 
studies in animal models cannot necessarily be applied 
to the human situation. Furthermore, the exact 
characterization of peptide hormone-receptor interac- 
tion requires the simultaneous measurement of binding 
characteristics and biological response parameters in 
order to evaluate signal transduction efficacy [9]. In 
this context, the functional impact of kinin hydroxyla- 
tion in the human situation remains to be established. 
The naturally occurring kinins include bradykinin 
(BK), Lys-BK and Met-Lys-BK. Recently, two other 
kinins were discovered in man. [Hydroxyproline3]- 
bradykinin ([Hyp3]-BK) was found in human urine 
[3,4]. It was also isolated from human malignant ascitic 
fluid and found to be active in the rat estrous uterus 
assay [5]. [Hyp3]-Lys-BK was obtained from human 
plasma’s Cohn’s fraction IV-4 [6] and from human 
purified kininogen after incubation with kallikrein [7]. 
In animal tissue studies, Fredrick et al. [8] reported that 
synthetic [Hyp3]-BK is as active as native BK in its abili- 
Cultured foreskin fibroblasts have successfully been 
used as a human model system for the study of kinin 
effects and B2 bradykinin receptors [lo]. Phospho- 
lipase C-induced formation of inositol phosphates has 
been shown to be an early occurring, sensitive para- 
meter of BK action in these cells [ll]. In addition, 
kinin-induced phospholipase AZ-dependent release of 
prostaglandins and accumulation of cyclic 3 ’ ,5 ’ -ade- 
nosine monophosphate (CAMP) have been demon- 
strated in fibroblasts [ 10,121. 
Therefore, these cells were utilized to investigate the 
effect of [Hyp3]-BK and [Hyp3]-Lys-BK on receptor 
binding properties and signal transduction processes. 
Correspondence address: A. Roscher, Abteilung fur Klinische 
Biochemie in der Kinderklinik der Universitlt Mtinchen, Lindwurm- 
stra8e 4, D 8000 Miinchen 2, FRG 2. MATERIALS AND METHODS 
Abbreviations: BK, bradykinin; IP, inositol monophosphate; IP2, in- 
ositol diphosphate; IPs, inositol triphosphate; PI, phosphatidyl- 
inositol; CAMP, cyclic 3 ’ ,5 ’ -adenosine monophosphate 
2.1. Materials 
[Hyp’]-BK and [Hyp’]-Lys-BK were purchased from Peptide In- 
stitute (Osaka, Japan). DesArg’[Leu*]-BK and D-Argo-[Hyp3,Thi5,s, 
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D-Phe7]-BK were generous gifts from D, Regoli (Sherbrooke, 
Canada). [2,3-Prolyl-3,4-3H(N)]bradykinin (spec. act. 80 Ci/mtnol) 
and myo-[2-3H]inositol (spec. act. 15 Ci/mmol) were from New 
England Nuclear (Boston, MA). ‘2sI-cAMP ra~oimmunoassay 
reagents were purchased from Amersham (~rau~chweig, FRG). All 
other chemicals were obtained from commercial sources and of the 
highest purity available. 
2.2. Cell culture 
Stock cultures of human foreskin fibroblasts were established and 
grown by standard procedures as described [lo]. 
2.3. Binding studies in solubilized receptor preparations 
Cells were grown on 145 mm dishes and incubated with 20 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Pipes), pH 6.8, 
containing 4 mM 3-(3-cholamidopropyl-dimethylammonio)-l-pro- 
panesulfonate (Chaps) for 15 min at 25°C. The soluble supernatant 
was passed through a 2pm membrane fifter and kept at 4°C. 
Solubilized proteins were incubated with [%I-BK at concentrations 
giving approximately half-maximal saturation of specific binding 
sites (& = 2 nM). Incubations were carried out in the presence or 
absence of various concentrations of BK-analogues and 2 mM 
bacitracin at 4°C for 2 h. Free ligand was separated from protein- 
bound f3H]-BK by rapid filtration through polyethylenimine-treated 
GFfC glass fiber filters (Whatman, M~dstone, UK). The filters were 
washed 3 times with 14% (v/v) isopropanol in Hz0 and total fllter- 
bound radioactivity was assayed by liquid scintillation counting. 
Non-specific binding was determined in the presence of a thousand- 
fold molar excess of unlabeled BK. 
2.4. Measurement of inos~tol phosphate production 
Fibroblasts were incubated for 48 h with OS ,&i/ml myo-[2-‘HIin- 
ositol in medium 199 (Seromed, Beriin, FRG) containing 0.1 Yo FCS. 
Thereafter, supernatants were aspirated and cells were washed 3 
times at 37°C with Hanks’ buffered salt solution (HBSS) including 
10 mM N-2-hydroxyethyl-piperazine-N’-2-ethanesulfonic acid 
(Hepes), pH 7.3. Cells were then allowed to equilibrate in the same 
solution containing 10 mM LiCl at 37’C for IS min to block 
inositol-1-phospha~se action. Peptides were then added for 60 s in 
a fresh 1 ml volume of medium per dish. The reaction was terminated 
by replacing the medium with 6OO,&dish of 10% (w/v) ice-cold 
trichloroacetic acid (TCA), and freezing the dish on dry-ice. Thawed 
cells plus supernatant were centrifuged for 10 min at 700 x g. Super- 
natants were then extracted 6 times with 6 ml of water-saturated 
diethylether to remove TCA. Aliquots of the aque.ous phase contain- 
ing the water-soluble [3HJinositol metabolites were applied on Dowex 
1 x 8 anion exchange columns for separation of inositol phosphates 
as described by Griffin and Hawthorne 1131. 
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2.5. Determination of cellular CAMP 
Confluent cells were incubated with HBSS including 2OO/cM 
isobutylmethy~~t~ne and stimulated with or without various con- 
centratgons of peptides for 7 min at 37”C, pH 7.4. The reaction was 
terminated by aspirating the medium, the addition of 1 ml of 5% 
(w/v) ice-cold TCA and placing the dish on dry-ice. After thawing, 
the supernatant was extracted 5 times with 10 ml of diethylether and 
aliquots were assayed for CAMP content using the radioimmunoassay 
procedure of Amersham (Braunschweig, FRO). 
3. RESULTS 
Kinin receptors in cultured human fibroblasts have 
been tentatively characterized as a B2 subtype by the 
criterion of typical rank order of potency of agonists 
[lo]. This notion is substantiated by the data shown in 
fig.lA. In the solubilized preparation, the protot~ic 
BI antagonist DesArg’[Leu*]-BK at a concentration of 
up to 1 PM was ineffective in displacing [3H]-BK, 
whereas the typical 182 antagonist D-Arg’[Hyp’, 
Thi5’*,D-Phe’]-BK was effective in concentrations 
equalling those of native BK. In this B2 receptor 
system, [Hyp3]-BK and [Hyp3]-Lys-BK were able to 
displace 13H]-BK from solubilized binding sites of 
cultured human fibroblasts in a dose-dependent man- 
ner, being at least equipotent with BK and Lys-BK 
(fig. 1B). 
After 48 h of a prior incubation of cells with 
0.5 &i/ml myo-~2-3H]inositol, the incorporation of 
radioactivity averaged 20 f 5%. Determination of 
membrane-bound [3H]inositol in the cell pellet showed 
between 30% (BK-stimulated) and 60% (non- 
stimulated) of cellular radioactivity, indicating BK- 
induced hydrolysis of membrane-associated phospho- 
lipids. The remaining intracellul~ water-soluble 
[3H]inositol fractions were further investigated. The 
magnitude of the accumulation and the proportions of 
the 3 inositol metabolites relative to each other were 
dependent on the concentration of the agonists applied 
and on the time of stimulation (data not shown). Fur- 
ther experiments indicated, that after 45-60 s of 
stimulation with kinins, IP3 accumulation reached a 
60 
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Fig. 1. Displacement of specific [‘H]BK binding to solubilized binding sites from human fibroblasts by agonists and antagonists. (A) Effects of 
BK receptor antagonists. Bi = DesArg’[Leu’]-BK; B2 = D-Arg”[Hyp3,Thi5*‘, D-Phe’]-BK. (B) Effects of BK, Lys-BK and [Hyp’]-kinins. 
Incubations were carried out with 2 nM [‘HI]-BK, and the indicated concen~ations of agonists and antagonists. So~ubili~tion and binding 
experiments were performed as described in section 2. Data are expressed as means of triplicate cultures of a representative experiment. 
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Table 1 4. DISCUSSION 
Effect of bradykinin (BK) and BK analogues on accumulation of 
water-soluble inositol phosphate metabolites 
Peptides [‘H]IP J3H]IPz l’Bl=‘s 
None (buffer) 5415 * 516 546 f 119 483 z.t 129 
Bradyki~n I6672 + 1070 14081 f 442 4384 f 213 
Met-Lys-BK 14547 * 1760 12040 f 1519 4408 zt 512 
[Hyp3]-BK 13372 f 1923 11971 f 1480 3973 f 405 
[Hyp3]-Lys-BK 15263 f 1115 12758 + 2061 4971 f 182 
Tyr*-BK 8973 -t 307 5029 * 197 2830 f 79 
Tyr’-BK 7418 f 1121 1616 -+ 163 1071 f 170 
DesArgg-BK 6522 rt 1565 2196 f 440 1432 -f 395 
Angiotensin II 6069 f 2012 2558 f 1028 1150 f 420 
Prelabeled cells were stimulated for 60 s at 37°C with 0.1 PM of the 
peptides, except for DesArgg-BK and angiotensin II, which were used 
at a concentration of 10 FM to test for non-specific effects. Inositol 
phosphates were separated and measured as described in section 2. 
Numbers represent dpm 3Hldish as the mean f SE of triplicate 
cultures 
maximum which was not superceded after 5 min. At 
60 s, the largest specific increases observed were for the 
IPz and IP3 fractions (table 1). A variety of BK 
analogues were studied for their potency to elicit a PI 
response at 60 s stimulation time (table 1). [Hyp’]-BK 
and [Hyp3]-Lys-BK led to a pronounced accumulation 
of inositol phosphates, as did the non-hydroxylated 
kinins BK and Met-Lys BK. Tyr’-BK and Tyr’-BK were 
less effective. DesArgg-BK and angiotensin II, serving 
as controls in the B2 system had only minims effects, 
even at a concentration of 10e5 M. 
The recent identification of hydroxylated kinins 
from human sources [3-61 has raised several questions. 
Hydroxylation of the kinin acceptor sequence of Pro- 
Pro-Gly is postulated to occur within the kininogen 
molecule due to posttranslation~ modi~cation by 
prolyl-4-hydroxylase [6,7,14]. This enzyme hydrox- 
ylates Xaa-Pro-Gly sequences within procollagen, 
where Xaa is typically proline or alanine [15]. In vitro 
studies have demonstrated that the ‘free’ peptides BK 
[ 161 and Lys-BK [17] serve as substrates for this en- 
zyme, but whether this holds true for in vivo situations 
is presently unknown. From data on the action of 
[Hyp3]-kinins on muscle contraction [7,8] one has to 
postulate that these compounds exert their effects 
through specific receptors. In this report we have in- 
vestigated specific binding properties and signal 
transduction processes of the hydroxylated kinins in 
cultured human foreskin fibroblasts, a B2 receptor 
system. 
From our data it can be concluded that the hydrox- 
ylated kinins have binding properties with the B2 recep- 
tor similar to the non-hydroxylated kinins. Possible 
interactions of these compounds with Bl receptors in 
other cell types remain to be established. Quantitative 
assessment of phosphoinositol responses to a variety of 
BK analogues including hydroxylated kinins showed 
correlation with their capability to displace [3H]-BK 
binding. 
In addition to phospholipase C activation, the effect 
of the hydroxylated kinins on phospholipase 
AZ-dependent signal generation was investigated. 
Kinin-induced CAMP accumulation was measured by 
radioimmunoassay. Stimulation by [Hyp3]-BK and 
[Hyp3]-Lys-BK resulted in an up to 16-fold increase of 
CAMP levels above control values in intact cells (table 
2). At 0.5 pM of kinin concentration, no significant 
differences between hydroxylated and the correspon- 
ding non-hydroxylated derivatives were observed. 
Again, DesArg’-BK was ineffective. 
These results are consistent with the hypothesis, that 
hydroxylated kinins are capable of activating both 
phospholipase C-dependent PI responses and 
phospholipase AZ-mediated CAMP generation with 
similar efficiency as native BK. Hence, other possible 
physiologic~ implications of kinin hydroxylation, e.g. 
on tissue distribution or elimination kinetics of the 
modified ligands, have to be considered to elucidate the 
role of posttranslational kinin modification, 
Table 2 
Effect of bradykinin and BK aualogues on CAMP production 
Peptides pm01 cAMP/mg protein 
None (buffer) 21 
Bradykinin 367 
Lys-BK 368 
[HYP’I-BK 317 
[Hyp’l-Lys-BK 334 
DesArgg-BK 17 
Confluent monolayers of human ~brobl~ts were incubated with 
HBSS containing 0.5 FM of the indicated peptides for 7 min at 37”~. 
The reaction was terminated and CAMP content measured as 
described in section 2. Values represent means of duplicate 
Acknowledgements: We wish to thank D. Regoli for kindly providing 
BK antagonists, M. Eulitz for quantitative amino acid determinations 
and J. Kaufmann for HPLC of bradykinin. The experimental help of 
P. Heinz-Erian and G. Kim is greatly appreciated, as are helpful 
discussions with M. Haasemann and C. Klier. This work was sup- 
ported by the Sonderforschungsbereich 207 of the University of 
Munich, Projects Fl and F4. 
REFERENCES 
111 
121 
131 
[41 
PI 
Miiller-Esterl, W., Iwanaga, S. and Nakanishi, S. (1986) Trends 
Biochem. Sci. 11, 336-339. 
Regoli, D. and Barabe, J. (1980) Pharmacol. Rev. 32, l-46. 
Kato, H., Matsumura, Y. and Maeda, H. (1988) FEBS Lett. 
232, 252-254. 
determinations 
Mindroiu, T., Carreto, O.A., Proud, D., Walz, D. and Scicli, 
A.G. (1988) Biochem. Biophys. Res. Commun. 152, 519-526. 
Maeda, H., Matsumura, Y. and Kato, H. (1988) J. Biol. Chem. 
263, 16051-16054. 
113 
Volume 262, number 1 FEBS LETTERS March 1990 
[6] Sasaguri, M., Ikeda, M., Ideishi, M. and Arakawa, K. (1988) 
Biochem. Biophys. Res. Commun. 150, 511-516. 
[‘I] Maier, M., Reissert, G., Jerabek, I., Lottspeich, F. and Binder, 
B.R. (1988) PEBS Lett. 232, 395-398. 
(81 Fredrick, M.J., Vavrek, R. J., Stewart, J.M. and Odya, C.E. 
(1984) Biochem. Pharmacol. 33, 2887-2892. 
[9] Laduron, P.M. (1987) in: Receptor Biochemistry and 
Methodology (Black, J.W., Jenkinson, D.M. and Gerskowitch, 
V.P. eds) ~01.6, pp.71-79, Alan R. Liss, New York. 
[lo] Roscher, A.A., Manganiello, V.C., Jelsema, CL. and Moss, J. 
(1983) J. Clin. Invest. 72, 626-635. 
[ll] Vincentini, L.M. and Villereal, M.L. (1984) Biochem. Biophys. 
Res. Commun. 123, 663-670. 
[12], Jelsema, C.L., Moss, J. and Manganiello, V.C. (1985) Methods 
Enzymol. 109, 480-503. 
[13] Griffin, H.D. and Hawthorne, J.N. (1978) Biochem. J. 176, 
541-552, 
1141 Miiller-Esterl, W. (1989) Thromb. Haemostas. 60, 2-6. 
[15] Prockop, D.J., Kivirikko, K.I., Tuderman, L. and Guzman, 
N.A. (1979) N. Engl. J. Med. 301, 13-23. 
[16] Rhoads, R.E. and Udenfriend, S. (1969) Arch. Biochem. 
Biophys. 133, 108-111. 
[17] McGee, J.O., Rhoads, R.E. and Udenfriend, S. (1971) Arch. 
Biochem. Biophys. 144, 343-351. 
114 
